Frequency of Barrett's neoplasia after initial negative endoscopy with biopsy: A long-term histopathological follow-up study

Endoscopy

Volumn 38, Issue 12, 2006, Pages 1201-1205

  Vieth, M ^a   Schubert, B ^a   Lang Schwarz, K ^a   Stolte, M ^a  

^a INSTITUTE OF PATHOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER GRADING; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT SELECTION; PRIORITY JOURNAL; SEX RATIO; UNITED KINGDOM; UNITED STATES;

ADENOCARCINOMA; BARRETT ESOPHAGUS; BIOPSY; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; ESOPHAGUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS;

EID: 33845704219     PISSN: 0013726X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-944993     Document Type: Article

References (29)

1. Murray L, Watson P, Johnston B et al. Risk of adenocarcinoma in Barrett's oesophagus: population based study. BMJ 2003; 327: 534-535
2. Hongo M, Shoji T. Epidemiology of reflux disease and CLE in East Asia. J Gastroenterol 2003: 38: 25-30
3. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002; 123: 461-467
4. Bytzer P, Christensen PB, Damkier P et al. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999; 94: 86-91
5. Pera M, Cameron AJ, Trastek VF et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104: 510-513
6. Bollschweiler E, Wolfgarten E, Gutschow C et al. Demographic variations in the rising incidence of esophageal adenocarcinorna in white males. Cancer 2001; 92: 549-555
7. Haggitt RC. Adenocarcinoma in Barrett's esophagus: a new epidemic? Hum Pathol 1992; 23: 475-476
8. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinorna in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313: 857-859
9. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 1249-1256
10. Conio M, Blanchi S, Lapertosa G et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinorna: a prospective study. Am J Gastroenterol 2003; 98: 1931-1939
11. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119: 333-338
12. Jankowski JA, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 2002: 122: 588-590
13. Gerson LB, Triadafilopoulos G. Screening for esophageal adenocarcinoma: an evidence-based approach. Am J Med 2002; 113: 499-505
14. Rex DK, Cummings OW, Shaw M et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003: 125: 1670-1677
15. Montgomery E, Bronner MP, Goldblum JR et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001; 32: 368-378
16. Ormsby AH, Petras RE, Henricks WH et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 2002: 51: 671-676
17. Lagergren J, Bergstrom R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831
18. Sampliner RE:Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97:1888-1895
19. Spechler SJ. Clinical practice. Barrett' s esophagus. N Engl J Med 2002; 346: 836-842
20. Hamilton SR, Aaltonen LA (eds). WHO Classification. Tumours of the digestive system. Lyon: IARC Press, 2000: 20
21. El-Serag HB, Aguirre TV, Davis S et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004; 99: 1877-1883
22. Hillman LC, Chiragakis L, Shadbolt B et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004; 180: 387-391
23. Koop H, Schepp W, Müller-Lissner S et al. Consensus conference of the DGVS on gastroesophageal reflux. Z Gastroenterol 2005; 43: 163-164
24. Raj A, Jankowski J. Acid suppression and chemoprevention in Barrett's oesophagus. Dig Dis 2004; 22: 171-180
25. Csendes A, Smok G, Burdiles P et al. Prevalence of intestinal metaplasia according to the length of the specialized columnar epithelium lining the distal esophagus in patients with gastroesophageal reflux Dis Esophagus 2003; 16: 24-28
26. Inadomi JM, Sampliner R, Lagergren J et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003: 138: 176-186
27. Ferguson MK, Durkin A. Long-term survival after esophagectomy for Barrett's adenocarcinoma in endoscopically surveyed and nonsurveyed patients. J Gastrointest Surg 2002; 6: 29-35
28. Incarbone R, Bonavina L, Saino G et al. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus. Surg Endosc 2002; 16: 263-266
29. vanSandick JW, vanLanschot JJ, Kuiken BW et al. Impact of endoscopic biopsy surveillance of Barretts oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998; 43: 216-222